Molecular mechanisms of psychiatric diseases

• Published in: Neurobiology of disease Vol. 146; p. 105136
• Main Authors: Blokhin, Ilya O., Khorkova, Olga, Saveanu, Radu V., Wahlestedt, Claes
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2020; Elsevier
• Subjects: Alcohol use disorder; DNA methylation; Histones; Major depressive disorder; Non-coding RNAs; Schizophrenia; Splicing; Non-coding RNAs; Alcohol use disorder; Splicing; Schizophrenia; DNA methylation; Histones; Major depressive disorder
• ISSN: 0969-9961; 1095-953X; 1095-953X
• DOI: 10.1016/j.nbd.2020.105136

For most psychiatric diseases, pathogenetic concepts as well as paradigms underlying neuropsychopharmacologic approaches currently revolve around neurotransmitters such as dopamine, serotonin, and norepinephrine. However, despite the fact that several generations of neurotransmitter-based psychotropics including atypical antipsychotics, selective serotonin reuptake inhibitors, and serotonin-norepinephrine reuptake inhibitors are available, the effectiveness of these medications is limited, and relapse rates in psychiatric diseases are relatively high, indicating potential involvement of other pathogenetic pathways. Indeed, recent high-throughput studies in genetics and molecular biology have shown that pathogenesis of major psychiatric illnesses involves hundreds of genes and numerous pathways via such fundamental processes as DNA methylation, transcription, and splicing. Current review summarizes these and other molecular mechanisms of such psychiatric illnesses as schizophrenia, major depressive disorder, and alcohol use disorder and suggests a conceptual framework for future studies.